The estimated Net Worth of Tracey L Mc Cain is at least $4.69 Миллион dollars as of 5 June 2024. Ms. Cain owns over 4,373 units of Blueprint Medicines Corp stock worth over $811,327 and over the last 8 years she sold BPMC stock worth over $978,413. In addition, she makes $2,900,570 as Chief Legal Officer и Chief Compliance Officer at Blueprint Medicines Corp.
Sign up
Ms. McCain BPMC stock SEC Form 4 insiders trading
Tracey has made over 11 trades of the Blueprint Medicines Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 4,373 units of BPMC stock worth $378,527 on 5 June 2024.
The largest trade she's ever made was exercising 25,000 units of Blueprint Medicines Corp stock on 23 September 2021 worth over $709,000. On average, Tracey trades about 2,003 units every 67 days since 2016. As of 5 June 2024 she still owns at least 9,373 units of Blueprint Medicines Corp stock.
You can see the complete history of Ms. Cain stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tracey McCain biography
Tracey L. McCain J.D. serves as Chief Legal Officer, Chief Compliance Officer of the Company. She has served as our executive vice president and chief legal officer and as our chief compliance officer. Prior to joining us, from January 2016 to September 2016, Ms. McCain served as Senior Vice President and Head of Legal of Sanofi Genzyme, a global business unit of Sanofi. Ms. McCain held roles of increasing responsibility after joining Genzyme Corporation, or Genzyme, in May 1997, including becoming its General Counsel after Genzyme was acquired by Sanofi in 2011. In her capacity as Senior Vice President and General Counsel of Genzyme from May 2011 to December 2015, she oversaw all aspects of its legal department in the United States and Europe, including general corporate, commercial and intellectual property matters. Prior to joining Genzyme, Ms. McCain was an associate at the law firm Palmer & Dodge LLP. Ms. McCain currently serves as a member of the board of directors and audit committee of Kiniksa Pharmaceuticals, Ltd. Ms. McCain holds a B.A. from the University of Pennsylvania with a major in political science and a J.D. from Columbia University School of Law.
What is the salary of Tracey McCain?
As the Chief Legal Officer и Chief Compliance Officer of Blueprint Medicines Corp, the total compensation of Tracey McCain at Blueprint Medicines Corp is $2,900,570. There are 4 executives at Blueprint Medicines Corp getting paid more, with Jeffrey Albers having the highest compensation of $9,362,370.
How old is Tracey McCain?
Tracey McCain is 52, she's been the Chief Legal Officer и Chief Compliance Officer of Blueprint Medicines Corp since 2017. There are 12 older and 14 younger executives at Blueprint Medicines Corp. The oldest executive at Blueprint Medicines Corp is Mark Goldberg, 65, who is the Independent Director.
What's Tracey McCain's mailing address?
Tracey's mailing address filed with the SEC is C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE 2 CHURCH STREET, HAMILTON, D0, HM 11.
Insiders trading at Blueprint Medicines Corp
Over the last 10 years, insiders at Blueprint Medicines Corp have traded over $126,865,732 worth of Blueprint Medicines Corp stock and bought 131,110 units worth $2,599,105 . The most active insiders traders include Llc Fmr, Kevin P Starr и Lonnel Coats. On average, Blueprint Medicines Corp executives and independent directors trade stock every 12 days with the average trade being worth of $1,362,195. The most recent stock trade was executed by Jeffrey W. Albers on 9 September 2024, trading 19,702 units of BPMC stock currently worth $1,685,900.
What does Blueprint Medicines Corp do?
blueprint medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. we are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. by focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. we see a substantial opportunity in kinase drug discovery and development
What does Blueprint Medicines Corp's logo look like?
Complete history of Ms. Cain stock trades at Blueprint Medicines Corp, Immunogen и Kiniksa Pharmaceuticals International Plc
Blueprint Medicines Corp executives and stock owners
Blueprint Medicines Corp executives and other stock owners filed with the SEC include:
-
Jeffrey Albers,
Chief Executive Officer, Director -
Christina Rossi,
Chief Commercial Officer -
Christopher Murray,
Senior Vice President, Technical Operations -
Kathryn Haviland,
Chief Operating Officer -
Tracey McCain,
Chief Legal Officer, Chief Compliance Officer -
Marion Dorsch,
Chief Scientific Officer -
Anthony Boral,
Chief Medical Officer -
Michael Landsittel,
Chief Financial Officer -
Jeffrey W. Albers J.D., M.B.A., MBA,
Chairman, CEO & Pres -
Jeffrey W. Albers M.B.A., J.D., MBA,
CEO, Pres & Director -
Kathryn Haviland,
Chief Operating Officer -
Tracey L. McCain Esq.,
Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec. -
Dr. Fouad Namouni M.D.,
Pres of R&D -
Tracey L. Mccain,
Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec. -
Michael Landsittel,
CFO & Treasurer -
Daniel Lynch,
Independent Chairman of the Board -
Nicholas Lydon,
Independent Director -
Charles Rowland,
Independent Director -
George Demetri,
Independent Director -
Lonnel Coats,
Independent Director -
Lynn Seely,
Independent Director -
Mark Goldberg,
Independent Director -
Alexis Borisy,
Director -
Alexis A. Borisy A.M.,
Co-Founder & Director -
Fouad Namouni,
President, Research & Development -
Debra Durso-Bumpus,
Chief Human Resource Officer -
Kristin Hodous,
IR Contact Officer -
Ariel Hurley,
Vice President - Finance, Controller -
Dr. Percy H. Carter M.B.A., Ph.D.,
Chief Scientific Officer -
Dr. Christopher K. Murray,
Sr. VP of Technical Operations -
Ariel Hurley,
Principal Accounting Officer, VP of Fin. & Controller -
Debra Durso-Bumpus,
Chief People Officer -
Dr. Fouad Namouni,
Pres of R&D -
Mark J Levin,
10% owner -
Rock Ventures Ii, L.P.Third...,
-
Kevin P Starr,
10% owner -
Habib J Dable,
-
John Tsai,
-
Daniella Beckman,
-
Christoph Lengauer,
Chief Scientific Officer -
L. Becker Hewes,
CHIEF MEDICAL OFFICER -
Percy H. Carter,
CHIEF SCIENTIFIC OFFICER -
Therapeutics, Inc. Tango,
Director -
Kate Haviland,
CHIEF EXECUTIVE OFFICER -
Philina Lee,
CHIEF COMMERCIAL OFFICER